Development and Regulatory Evaluation of Biosimilars

Biologics are large molecules—hormones, cytokines, monoclonal antibodies, vaccines—created by the process of recombinant DNA technology in living cells. These products have greatly contributed to therapeutic breakthroughs in oncology and inflammatory disorders among others. As patents for many of these biologics begin to expire in the next few years, opportunities arise for developing generic versions of […]